Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1756 • ACR Convergence 2020
Comparable Long-Term Outcomes Among DAS28-ESR-based Remission Criteria and ACR/EULAR Definitions in Patients with Established Rheumatoid Arthritis
Felipe Julio Ramirez Garcia¹, Jose Inciarte-Mundo², Andrea Cuervo³, Raquel Celis⁴, Virginia Ruiz-Esquide⁴, Raul Castellanos-Moreira⁵, Andres Ponce⁴, Jose Gómez-Puerta⁶, Raimon Sanmartí⁶ and Juan Cañete⁷, ¹Arthritis Unit, Rheumatology Dpt, Hospital Clinic, Barcelona, Spain, Barcelona, Catalonia, Spain, ²Hospital Universitari Clínic de Barcelona, Barcelona, ³Hospital Clínic, Barcelona, Spain, ⁴Hospital Clinic, Barcelona, Spain, ⁵Hospital Clinic of Barcelona, Barcelona, Spain, ⁶Hospital Universitari Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁷Arthritis Unit, Rheumatology Dpt, Hospital Clinic, Barcelona, Spain and IDIBAPS, Barcelona, Spain
Background/Purpose: To compare long-term clinical and radiographic outcomes among five sets of remission criteria [four clinical and one Ultrasound (US)-based] in a cohort of RA…
Abstract Number: 1897 • ACR Convergence 2020
Trends in Hospitalizations for Vertebral Compression Fractures in Ankylosing Spondylitis: Data from the National Inpatient Sample 2001-2014
Anish Paudel¹, Rashmi Dhital², Dilli Poudel³, Anthony Donato¹ and Paras Karmacharya⁴, ¹Reading Hospital and Medical Center, West Reading, PA, ²Reading Hospital and Medical Center, West Reading, ³University of Pennsylvania, Philadelphia, PA, ⁴Mayo Clinic, Rochester MN, ROCHESTER, MN
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease predominantly affecting the spine, leading to syndesmophyte formation, ankylosis, and osteoporosis. These factors have been associated…
Abstract Number: 1998 • ACR Convergence 2020
Ten-year Analysis of the Risk of Severe Outcomes Related to Very Low-dose Glucocorticoids in Early Rheumatoid Arthritis
Camille Roubille¹, Amandine Coffy², Nathalie Rincheval², Jean Pierre Daures², René-Marc Flipo³, Maxime Dougados⁴ and Bernard Combe⁵, ¹CHU LAPEYRONIE, Montpellier, France, ²INSERM, Montpellier, France, ³Univ-Lille, CHU Lille, department of rheumatology, Lille, France, ⁴Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France, ⁵University of Montpellier, Montpellier, France
Background/Purpose: Although glucocorticoids (GC) remain an essential part of the therapeutic strategy in Rheumatoid Arthritis (RA), the long-term risk of adverse events of low-dose GC…
Abstract Number: 2045 • ACR Convergence 2020
Resident Memory T Cells in Synovial Tissue Mediate Arthritis Flares
Margaret Chang¹, Anais Levescot², Nathan Nelson-Maney², Rachel Blaustein², Kellen Winden¹, Allyn Morris³, Spoorthi Balu³, Alexandra Wactor², Ricardo Grieshaber-Bouyer⁴, Kevin Wei⁵, Lauren Henderson⁶, Rachael Clark³, Deepak Rao², Robert Fuhlbrigge⁷ and Peter Nigrovic⁸, ¹Boston Children's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, Heidelberg, Germany, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Boston Children's Hospital, Watertown, MA, ⁷University of Colorado, Denver, CO, ⁸Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston
Background/Purpose: Resident memory T cells (TRM) are site-specific memory T cells that take up long-term residence in peripheral tissues and aid in local immune defense.…
Abstract Number: 0058 • ACR Convergence 2020
Drug Retention and Discontinuation of Biological DMARDs and Novel Small Molecules: Data from the Singapore National Biologics Registry
Li Wearn Koh¹, Man Hua Aw², Preeti Dhanasekaran³, Rosa Lim Mui San¹, Stephanie Wong⁴, Xanthe Chua⁵, Wei Joo Choy¹, Manjari Lahiri⁶ and Siaw Ing Yeo², ¹Tan Tock Seng Hospital, Singapore, Singapore, ²Singapore General Hospital, Singapore, Singapore, ³National University of Singapore, Singapore, Singapore, ⁴Clinical Research and Innovation Office, Tan Tock Seng Hospital Singapore, Singapore, Singapore, ⁵Tan Tock Seng Hospital, Singapore, Singapore, Singapore, ⁶National University Hospital, Singapore, Singapore
Background/Purpose: To describe drug retention rate and reasons for discontinuation of biological disease modifying anti-rheumatic drugs ( bDMARD) and novel small molecules in patients from…
Abstract Number: 0136 • ACR Convergence 2020
Filgotinib Significantly Improved Patient-reported Health-related Quality of Life for Patients with Active Rheumatoid Arthritis: A Post Hoc Analysis of SF-36 and HAQ-DI from Phase 3 Studies
Clifton Bingham III¹, David Walker², Peter Nash³, Susan Lee⁴, Lei Ye⁴, Hao Hu⁴, Javaria Mona Khalid⁵ and Bernard Combe⁶, ¹Johns Hopkins University, Baltimore, MD, ²Northumbria Healthcare NHS Foundation Trust, North Shields, United Kingdom, ³School of Medicine Griffith University, Brisbane, Queensland, Australia, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos BV, Leiden, Netherlands, ⁶University of Montpellier, Montpellier, France
Background/Purpose: Reduction in pain and fatigue, maintenance of physical functioning, and improvement in health-related quality of life (HRQoL) are vital aspects of successful treatment for…
Abstract Number: 0163 • ACR Convergence 2020
Cost of Non-Persistence in the Treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors of Inflammatory Arthritis: A Propensity Score Matching Approach
Johan Dalén¹, Karin Luttropp¹, Tor Olofsson², Christopher Black³ and Amy Puenpatom⁴, ¹ICON plc, Stockholm, Sweden, Stockholm, Sweden, ²Department of Clinical Sciences, Lund, Rheumatology, Lund University, Sweden; Department of Rheumatology, Skåne University Hospital, Lund, Sweden, Lund, Sweden, ³Merck & Co., Inc., Kenilworth, NJ, USA, Rahway, NJ, ⁴Merck & Co., Inc., Kenilworth, NJ, USA, North Wales, PA
Background/Purpose: Few studies have explored cost consequences of non-persistence in the treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors (SC-TNFi) in Inflammatory Arthritis (IA; rheumatoid arthritis…
Abstract Number: 0193 • ACR Convergence 2020
Patients with Asthma Have a Higher Risk of Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Nipith Charoenngam¹, Ben Ponvilawan¹, Thanitsara Rittiphairoj¹, Surapa Tornsatitkul¹, Phuuwadith Wattanachayakul¹, Pongprueth Rujirachun¹ and Patompong Ungprasert², ¹Mahidol University, Bangkok, Thailand, ²Cleveland Clinic, Cleveland, OH, Cleveland Heights, OH
Background/Purpose: Studies have reported the association between asthma and elevated risk of several chronic diseases, such as inflammatory bowel disease, diabetes mellitus and coronary heart…
Abstract Number: 0209 • ACR Convergence 2020
Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate: Results at 84 Weeks
Josef Smolen¹, Paul Emery², William Rigby³, Yoshiya Tanaka⁴, Juan Vargas⁵, Nemanja Damjanov⁶, Manish Jain⁷, Yanna Song⁸, Nasser Khan⁹, Jeffrey Enejosa⁹ and Stanley Cohen¹⁰, ¹Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom, ³Dartmouth College, Norwichi, VT, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵Quantum Research, Puerto Varas, Chile, ⁶University of Belgrade Medical School, Belgrade, Serbia, ⁷Great Lakes Clinical Trials, Chicago, IL, ⁸AbbVie Inc., North Chicago,, IL, ⁹AbbVie Inc., North Chicago, IL, ¹⁰Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: In the SELECT-MONOTHERAPY trial, upadacitinib (UPA), an oral JAK inhibitor, demonstrated significantly greater efficacy compared to continuing methotrexate (MTX) when used as monotherapy over…
Abstract Number: 0226 • ACR Convergence 2020
Similar Efficacy of Sarilumab Monotherapy (MONARCH) vs Sarilumab and Methotrexate Combination Therapy (MOBILITY B) in Patients with Rheumatoid Arthritis
Gerd Burmester¹, Vivian Bykerk², Maya Buch³, Yoshiya Tanaka⁴, Hideto Kameda⁵, Amy Praestgaard⁶, Hubert van Hoogstraten⁷, Antonio Fernandez-Nebro⁸ and Thomas Huizinga⁹, ¹Charité University Hospital Berlin, Berlin, Germany, ²Hospital for Special Surgery, New York, NY, ³Centre of Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, United Kingdom, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵Toho University, Tokyo, Japan, ⁶Sanofi, Cambridge, MA, ⁷Sanofi, Bridgewater, NJ, ⁸University of Malaga, Malaga, Spain, ⁹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Sarilumab, as monotherapy or in combination with conventional synthetic DMARDs like methotrexate (MTX) has demonstrated improvement in symptomatic and functional outcomes in patients (pts)…
Abstract Number: 0316 • ACR Convergence 2020
High-sensitivity 18F-FDG PET/CT: A Diagnostic Tool for Psoriatic Arthritis
Siba Raychaudhuri¹, Yasser Abdelhafez², Soumajyoti Sarkar³, Smriti Raychaudhuri⁴ and Abhijit Chaudhari², ¹Division of Rheumatology, Allergy & Clinical Immunology, University of California School of Medicine, Davis, and VA Medical Center Sacramento, Sacramento, CA, ²University of California, Davis, Sacramento, CA, ³University of California, Davis, Davis, ⁴VA Sacramento Medical Center, Davis, CA
Background/Purpose: To validate high-sensitivity PET/CT as a diagnostic test we have explored the association of total-body and extremity PET/CT measures with the standardized psoriatic arthritis…
Abstract Number: 0486 • ACR Convergence 2020
Differences in Low-density Lipoprotein (LDL) Particle Composition and Oxidation May Underlie the Paradoxical Association of Low LDL with Higher Coronary Atherosclerosis Burden in Rheumatoid Arthritis
George Karpouzas¹, Sarah Ormseth¹, Elizabeth Hernandez¹ and Matthew Budoff¹, ¹Harbor-UCLA Medical Center and the Lundquist Institute, Torrance, CA
Background/Purpose: Rheumatoid arthritis (RA) patients in the lowest LDL group (< 70mg/dl) experience unexpectedly high cardiovascular risk. We first explored whether this group (Group 1)…
Abstract Number: 0589 • ACR Convergence 2020
The Ideal Mhealth Application for Rheumatoid Arthritis: Qualitative Findings from Stakeholder Focus Groups
Diederik De Cock¹, Maryline Vandeputte², Rani Van Melder², Michael Doumen², Delphine Bertrand¹, Veerle Stouten¹, Sofia Pazmino¹, Rene Westhovens³ and Patrick Verschueren⁴, ¹KU Leuven, Leuven, Belgium, ²KU Leuven, Leuven, ³University Hospitals Leuven, Belgium, Leuven, Belgium, ⁴University Hospital Leuven, Leuven, Belgium
Background/Purpose: Early access to specialized rheumatological care is under increasing pressure. Many countries are currently confronted with a relative shortage of practicing rheumatologists, while recent…
Abstract Number: 0751 • ACR Convergence 2020
Serum Interferon-Alpha Levels Could Help Identify a Subgroup of Rheumatoid Arthritis with Poorer Physical Function and Higher Physician Global Assessment
Yong Gil Hwang¹, Lei Zhu², Dongwen Wu² and Larry Moreland³, ¹University of Pittsburgh Physicians, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³University of Colorado, Colorado
Background/Purpose: Our objective was to identify the clinical significance of serum interferon-alpha levels in patients with established rheumatoid arthritis (RA).Methods: Serum samples and clinical data…
Abstract Number: 0768 • ACR Convergence 2020
Dynamics of Follicular Helper T Cells Subsets in Rheumatoid Arthritis Patients Before and After Treatment
Paola Virginia Ferrero¹, Luisina Onofrio¹, Cristina del Valle Acosta¹, Estefania Raquel Zacca¹, Nicolas Eric Ponce², Eduardo Mussano¹, Ignacio Isaac Cadile¹, Laura Onetti¹, Marina Werner¹, Alicia Beatriz Costantino¹, Eva Virginia Acosta Rodriguez³ and Adriana Gruppi², ¹HOSPITAL NACIONAL DE CLINICAS, FACULTAD DE MEDICINA, UNIVERSIDAD NACIONAL DE CORDOBA, CORDOBA, Cordoba, Argentina, ²FACULTAD DE CIENCIAS QUIMICAS, UNIVERSIDAD NACIONAL DE CORDOBA. CENTRO DE INVESTIGACIONES EN BIOQUIMICA CLINICA E INMUNOLOGIA, CORDOBA, Cordoba, Argentina, ³FACULTAD DE CIENCIAS QUIMICAS, UNIVERSIDAD NACIONAL DE CORDOBA. CENTRO DE INVESTIGACIONES EN BIOQUIMICA CLINICA E INMUNOLOGIA, CORDOBA, Argentina
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory disease characterized by the production of autoantibodies like rheumatoid factor and anti- citrullinated protein. CD4+ follicular helper T…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].